Clik here to view.
Antibodies: $75B in sales and no slow-down in sight
By Dawn M. Ecker (deckerbptccom) Antibody related products[i] have been a staple in the biopharmaceutical landscape for over 10 years. In preparing a recently published article on antibody related...
View ArticleClik here to view.
Big, bigger, but will they be the biggest? The past, present and future of...
By Dawn M. Ecker (deckerbptccom) The modern biotechnology era began in 1982 with the approval of Humulin in 1982[a], the first recombinant product. Throughout its 32 years of existence, the...
View ArticleClik here to view.
14th Annual Contract Pharma Conference and Exhibition
Based on current data from BPTC’s proprietary bioTRAK database, Dawn M. Ecker, Consultant, will be delivering a presentation on, “The Potential Impact of Biosimilars on Biomanufacturing Capacity” at...
View ArticleClik here to view.
11 New Monoclonal Antibodies in Regulatory Review Spells Bright Future Ahead
By Al Doig (adoigbptccom) Since the approval of Orthoclone OKT3 in 1986, the therapeutic monoclonal antibody industry has experienced three decades of continuous growth. Today there are over 40...
View ArticleClik here to view.
2015 – A Record Year for Antibody Product Approvals, But Not For...
By: Dawn M. Ecker (deckerbptccom) Recombinant biopharmaceutical products have been a growing sector in the pharmaceutical landscape for over 10 years and antibody related products[i] are undoubtedly...
View ArticleClik here to view.
BIO International Convention 2016
Title: BIO International Convention 2016 Location: San Francisco, CA. Description: Join BPTC at the annual BIO International Convention 2016 in beautiful San Francisco, CA from June 6-9, 2016 to...
View ArticleClik here to view.
Opportunities for Continuous Manufacturing in Biopharmaceutical Production
Thomas C. Ransohoff, M.S., Vice President and Principal Consultant at BPTC, gave a presentation entitled “Opportunities for Continuous Manufacturing in Biopharmaceutical Production” at the World...
View ArticleClik here to view.
No Slowdown for Antibody Product Approvals in 2017
by: Dawn M. Ecker Antibody related products[1] have been a staple in the biopharmaceutical landscape for over 10 years. In preparing a chapter for a soon to be published road map for developing...
View Article
